Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants orphan designation to Iomab-B

Oct. 19, 2016

EMA grants PRIME access to Atara's EBV-CTL

Oct. 19, 2016

PTC Therapeutics offers U.S. and E.U. regulatory update on Translarna

Oct. 18, 2016

Positive opinion handed down in E.U. for SomaKit TOC

Oct. 18, 2016

EMA gives orphan drug designation to Eiger's exendin 9-39

Oct. 18, 2016

AbbVie receives positive opinion for Venclyxto tablets in patients with difficult-to-treat CLL

Oct. 17, 2016

Bristol-Myers Squibb receives positive CHMP opinion for nivolumab

Oct. 17, 2016

EMA committee recommends approval of Rekovelle

Oct. 17, 2016

Obeticholic acid granted positive CHMP opinion as treatment of primary biliary cholangitis

Oct. 17, 2016

Full results from European phase III study of Infacort in pediatric adrenal insufficiency

Oct. 13, 2016

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...